收稿日期: 2023-10-25
网络出版日期: 2024-03-08
基金资助
安徽省教育厅自然科学研究项目(KJ2021A0816)
Expression of SLC35A2 and PFDN2 in breast cancer and its relationship with clinical observables and prognosis
Received date: 2023-10-25
Online published: 2024-03-08
目的 研究SLC35A2、前叶黄素亚基2（PFDN2）在乳腺癌中的表达及其与临床观察指标和预后的关系。 方法 使用TCGA数据库及TIMER 2.0数据库分析SLC35A2、PFDN2在乳腺癌组织及癌旁组织中的表达差异；K-M数据库绘制两者高、低表达组患者的生存曲线。qRT-PCR及免疫组化法检测SLC35A2、PFDN2在癌和癌旁组织的表达，统计学分析两者在两组织中的表达差异及其表达水平与临床观察指标之间的关系，并筛选出乳腺癌独立预后因素；将两者按表达水平分组，使用K-M生存分析比较各组预后差异并绘制生存曲线。 结果 生信、qRT-PCR及免疫组化结果显示SLC35A2、PFDN2在乳腺癌癌组织中表达水平显著高于癌旁组织。SLC35A2的表达与淋巴结转移情况显著相关，PFDN2的表达与肿瘤直径及淋巴结转移情况显著相关，两者高表达是乳腺癌的独立预后因素，两者均为高表达的患者预后最差。 结论 乳腺癌组织中SLC35A2和PFDN2的表达与临床观察指标和乳腺癌预后密切相关，可作为乳腺癌治疗的潜在靶点。
宋子旭 , 朱光正 , 郭晨旭 , 武佳琪 , 张立功 , 钱军 . SLC35A2、前叶黄素亚基2在乳腺癌中的表达及其与临床观察指标和预后的关系[J]. 实用医学杂志, 2024 , 40(4) : 496 -502 . DOI: 10.3969/j.issn.1006-5725.2024.04.010
Objective To investigate the expression of SLC35A2 and PFDN2 in breast cancer and their relationship with clinical indicators and prognosis. Methods TCGA database and TIMER 2.0 database were used to analyze the differences of SLC35A2 and PFDN2 expression in breast cancer tissues and paracancerous tissues； K?M database was used to create the survival curves of patients in the high and low expression groups of the two. qRT?PCR and immunohistochemistry were used to detect the expression of SLC35A2 and PFDN2 in the cancerous and paracancerous tissues， and the expression differences， the relationship between their expression levels and the clinical observation indexes were statistically analyzed， and the independent prognostic factors of breast cancer were screened out； K?M survival analysis was used to compare the prognostic differences between the groups and create the survival curves. Results The expression levels of SLC35A2 and PFDN2 in breast cancer tissues were significantly higher than those in paracancerous tissues according to the results of biopsy， qRT?PCR and immunohistochemistry， and the expression levels of SLC35A2 were significantly correlated with lymph node metastasis， while the expression of PFDN2 was significantly correlated with the diameter of the tumor and the metastasis of lymph nodes， and the expression of SLC35A2 and PFDN2 was an independent prognostic factor for breast cancer. patients had the worst prognosis. Conclusion The expression of SLC35A2 and PFDN2 in breast cancer tissues was closely related to clinical indicators and prognosis of breast cancer， and could be used as a potential target for breast cancer treatment.
Key words： breast cancer; SLC35A2; PFDN2; prognosis
| 1 | WILKINSON L， GATHANI T. Understanding breast cancer as a global health concern［J］. Br J Radiol， 2022，95（1130）：20211033. doi:10.1259/bjr.20211033 |
| 2 | SIEGEL R L， MILLER K D， WAGLE N S， et al. Cancer statistics， 2023［J］. CA Cancer J Clin， 2023，73（1）：17-48. doi:10.3322/caac.21763 |
| 3 | SUNG H， FERLAY J， SIEGEL R L， et al. Global Cancer Statistics 2020： GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries［J］. CA Cancer J Clin， 2021，71（3）：209-249. doi:10.3322/caac.21660 |
| 4 | HUANG Z， HU C， LIU K， et al. Risk factors， prognostic factors， and nomograms for bone metastasis in patients with newly diagnosed infiltrating duct carcinoma of the breast： a population-based study［J］. BMC Cancer， 2020，20（1）：1145. doi:10.1186/s12885-020-07635-1 |
| 5 | ZHAO H. The prognosis of invasive ductal carcinoma， lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast［J］. Breast Cancer， 2021，28（1）：187-195. doi:10.1007/s12282-020-01146-4 |
| 6 | TRAYES K P， COKENAKES S. Breast Cancer Treatment［J］. Am Fam Physician， 2021，104（2）：171-178. |
| 7 | JACOBS A T， MARTINEZ CASTANEDA-CRUZ D， ROSE M M， et al. Targeted therapy for breast cancer： An overview of drug classes and outcomes［J］. Biochem Pharmacol， 2022，204：115209. doi:10.1016/j.bcp.2022.115209 |
| 8 | RODRIGUES-FERREIRA S， NAHMIAS C. Predictive biomarkers for personalized medicine in breast cancer［J］. Cancer Lett， 2022，545：215828. doi:10.1016/j.canlet.2022.215828 |
| 9 | HAYKAL M M， RODRIGUES-FERREIRA S， NAHMIAS C. Microtubule-Associated Protein ATIP3， an Emerging Target for Personalized Medicine in Breast Cancer［J］. Cells， 2021，10（5）：1080. doi:10.3390/cells10051080 |
| 10 | NAJJAR S， ALLISON K H. Updates on breast biomarkers［J］. Virchows Arch， 2022，480（1）：163-176. doi:10.1007/s00428-022-03267-x |
| 11 | BARBA C， BLUMCKE I， WINAWER M R， et al. Clinical Features， Neuropathology， and Surgical Outcome in Patients With Refractory Epilepsy and Brain Somatic Variants in the SLC35A2 Gene［J］. Neurology， 2023，100（5）：e528-e542. doi:10.1212/wnl.0000000000201471 |
| 12 | 郭丽萍， 张国淳， 陈博，等. UGT1A1基因多态性与乳腺癌临床病理特征的相关性［J］. 实用医学杂志，2020，36（1）：1-5. doi:10.3969/j.issn.1006-5725.2020.01.001 |
| 13 | LIU C L， CHENG S P， HUANG W C， et al. Aberrant Expression of Solute Carrier Family 35 Member A2 Correlates With Tumor Progression in Breast Cancer［J］. In Vivo， 2023，37（1）：262-269. doi:10.21873/invivo.13076 |
| 14 | HE Q， DING Z， CHEN T， et al. PFDN2 promotes cell cycle progression via the hnRNPD-MYBL2 axis in gastric cancer［J］. Front Oncol， 2023，13：1164070. doi:10.3389/fonc.2023.1164070 |
| 15 | VALS M A， ASHIKOV A， ILVES P， et al. Clinical， neuroradiological， and biochemical features of SLC35A2-CDG patients［J］. J Inherit Metab Dis， 2019，42（3）：553-564. doi:10.1002/jimd.12055 |
| 16 | XU S， CHEN X， FANG J， et al. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2［J］. Front Immunol， 2023，14：1155182. doi:10.3389/fimmu.2023.1155182 |
| 17 | GIAMOUGIANNIS P， MARTIN-HIRSCH P L， MARTIN F L. The evolving role of MUC16 （CA125） in the transformation of ovarian cells and the progression of neoplasia［J］. Carcinogenesis， 2021，42（3）：327-343. doi:10.1093/carcin/bgab010 |
| 18 | LUO G， JIN K， DENG S， et al. Roles of CA19-9 in pancreatic cancer： Biomarker， predictor and promoter［J］. Biochim Biophys Acta Rev Cancer， 2021，1875（2）：188409. doi:10.1016/j.bbcan.2020.188409 |
| 19 | MATSUMOTO Y， JU T. Aberrant Glycosylation as Immune Therapeutic Targets for Solid Tumors［J］. Cancers （Basel）， 2023，15（14）：3536. doi:10.3390/cancers15143536 |
| 20 | SCOTT D A， DRAKE R R. Glycosylation and its implications in breast cancer［J］. Expert Rev Proteomics， 2019，16（8）：665-680. doi:10.1080/14789450.2019.1645604 |
| 21 | HADLEY B， LITFIN T， DAY C J， et al. Nucleotide Sugar Transporter SLC35 Family Structure and Function［J］. Comput Struct Biotechnol J， 2019，17：1123-1134. doi:10.1016/j.csbj.2019.08.002 |
| 22 | 莫绍剑. PFDN2在肝细胞癌中的表达及其临床意义［D］：太原：山西医科大学. |
| 23 | TAHMAZ I， SHAHMORADI GHAHE S， TOPF U. Prefoldin Function in Cellular Protein Homeostasis and Human Diseases［J］. Front Cell Dev Biol， 2021，9：816214. doi:10.3389/fcell.2021.816214 |
| 24 | MO S J， ZHAO H C， TIAN Y Z， et al. The Role of Prefoldin and Its Subunits in Tumors and Their Application Prospects in Nanomedicine［J］. Cancer Manag Res， 2020，12：8847-8856. doi:10.2147/cmar.s270237 |
| 25 | YESSEYEVA G， AIKEMU B， HONG H， et al. Prefoldin subunits （PFDN1-6） serve as poor prognostic markers in gastric cancer［J］. Biosci Rep， 2020，40（2）：BSR20192712. doi:10.1042/bsr20192712 |
/
| 〈 |
|
〉 |